MabThera®/Rituxan® (rituximab) (Rituximab)

Mabthera-1600-740

MabThera is the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukaemia. MabThera attacks these cells both directly and together with the body’s immune system.

In the United States, Europe and in additional countries, MabThera is approved for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated chronic lymphocytic leukaemia. In the United States, Japan and Canada MabThera is marketed as Rituxan.

MabThera® SC/ Rituxan Hycela™ (rituximab/hyaluronidase human)

The subcutaneous (SC) formulation of MabThera provides a more convenient option of administering MabThera. MabThera SC administered subcutaneously (under the skin) over the 5-7 minutes can reduce administration times dramatically and may provide significant benefits for patients, healthcare professionals and healthcare systems compared to intravenous MabThera infusion.

The MabThera SC formulation contains the exact same antibody (Active Pharmaceutical Ingredient or API) as the IV-administered MabThera.
In the United States, Europe and in additional countries, MabThera SC is approved for the treatment of adults with the following blood cancers:

• MabThera SC 1400mg - in previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma
• MabThera SC 1600 mg - in previously untreated and previously treated chronic lymphocytic leukaemia.

In the United States, Japan and Canada MabThera SC is marketed as Rituxan Hycela.